Peroxisome proliferator-activated receptor-alpha agonists repress expression of thrombin-activatable fibrinolysis inhibitor by decreasing transcript stabilityMASUDA, Yutaka; SAOTOME, Dan; TAKADA, Kimihiko et al.Thrombosis and haemostasis. 2012, Vol 108, Num 1, pp 74-85, issn 0340-6245, 12 p.Article

Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitorDEVELTER, Jan; DEWILDE, Maarten; GILS, Ann et al.Thrombosis and haemostasis. 2009, Vol 102, Num 1, pp 69-75, issn 0340-6245, 7 p.Article

Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient miceMAO, Shi-Shan; HOLAHAN, Marie A; BAILEY, Carolyn et al.Blood coagulation & fibrinolysis. 2005, Vol 16, Num 6, pp 407-415, issn 0957-5235, 9 p.Article

Nobiletin, a polymethoxyflavone in citrus fruits, reduces TAFI expression in HepG2 cells through transcriptional inhibitionTAKADA, Kimihiko; SEIKE, Toru; SASAKI, Tomoyuki et al.Thrombosis and haemostasis. 2013, Vol 109, Num 6, pp 1060-1069, issn 0340-6245, 10 p.Article

Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assayANTOVIC, Jovan P; ANTOVIC, Aleksandra.Thrombosis and haemostasis. 2003, Vol 90, Num 4, pp 620-627, issn 0340-6245, 8 p.Article

Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancyMOUSA, Hatem A; DOWNEY, Colin; ALFIREVIC, Zarko et al.Thrombosis and haemostasis. 2004, Vol 92, Num 5, pp 1025-1031, issn 0340-6245, 7 p.Article

Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiographySCHROEDER, Verena; CHATTERJEE, Tushar; MEHTA, Haresh et al.Thrombosis and haemostasis. 2002, Vol 88, Num 6, pp 1020-1025, issn 0340-6245, 6 p.Article

Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complicationsANTOVIC, Jovan P; YNGEN, Marianne; ÖSTENSON, Claes-Göran et al.Blood coagulation & fibrinolysis. 2003, Vol 14, Num 6, pp 551-556, issn 0957-5235, 6 p.Article

The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activityLIN, Joellen H. H; NOVAKOVIC, Dragana; RIZZO, Christina M et al.Thrombosis and haemostasis. 2013, Vol 109, Num 6, pp 1033-1044, issn 0340-6245, 12 p.Article

Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris: The APRAIS studyBROUWERS, Geert-Jan; LEEBEEK, Frank W. G; TANCK, Michael W. T et al.Thrombosis and haemostasis. 2003, Vol 90, Num 1, pp 92-100, issn 0340-6245, 9 p.Article

Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cellsLIN, Joellen H. H; GARAND, Mathieu; ZAGORAC, Branislava et al.Thrombosis and haemostasis. 2011, Vol 105, Num 6, pp 999-1009, issn 0340-6245, 11 p.Article

Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myelomaBALCIK, Ozlem S; ALBAYRAK, Murat; UYAR, Mehtap E et al.Blood coagulation & fibrinolysis. 2011, Vol 22, Num 4, pp 260-263, issn 0957-5235, 4 p.Article

Genetic and environmental influences on the fibrinolytic system: a twin studyPEETZ, Dirk; VICTOR, Anja; ADAMS, Petra et al.Thrombosis and haemostasis. 2004, Vol 92, Num 2, pp 344-351, issn 0340-6245, 8 p.Article

Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanismCOLUCCI, Mario; BINETTI, Bianca M; TRIPODI, Armando et al.Blood. 2004, Vol 103, Num 6, pp 2157-2161, issn 0006-4971, 5 p.Article

Factor IX-Padua enhances the fibrinolytic resistance of plasma clotsAMMOLLO, Concetta T; SEMERARO, Fabrizio; COLUCCI, Mario et al.Thrombosis and haemostasis. 2014, Vol 111, Num 2, pp 226-232, issn 0340-6245, 7 p.Article

The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosisMARTINI, C. H; BRANDTS, A; DE BRUIJNE, E. L. E et al.British journal of haematology. 2006, Vol 134, Num 1, pp 92-94, issn 0007-1048, 3 p.Article

TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammationHUGENHOLTZ, Greg C. G; MEIJERS, Joost C. M; ADELMEIJER, Jelle et al.Thrombosis and haemostasis. 2013, Vol 109, Num 5, pp 948-955, issn 0340-6245, 8 p.Article

Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic strokeROOTH, Elisabeth; WALLEN, Hakan; ANTOVIC, Alexandra et al.Blood coagulation & fibrinolysis. 2007, Vol 18, Num 4, pp 365-370, issn 0957-5235, 6 p.Article

Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) is up-regulated by increase in intracellular cyclic AMP levels in cultured HepG2 cellsISHII, Hidemi; KOJIMA, Yuka; MASUDA, Yutaka et al.Thrombosis and haemostasis. 2009, Vol 102, Num 6, pp 1204-1211, issn 0340-6245, 8 p.Article

The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitorVERKLEIJ, Chantal J. N; NIEUWDORP, Max; GERDES, Victor E. A et al.Thrombosis and haemostasis. 2009, Vol 102, Num 3, pp 460-468, issn 0340-6245, 9 p.Article

Measurement of procarboxypeptidase U (TAFI) in human plasma : A laboratory challengeWILLEMSE, Johan L; HENDRIKS, Dirk F.Clinical chemistry (Baltimore, Md.). 2006, Vol 52, Num 1, pp 30-36, issn 0009-9147, 7 p.Article

Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancyWATANABE, Takashi; MINAKAMI, Hisanori; SAKATA, Yoichi et al.Gynecologic and obstetric investigation. 2004, Vol 58, Num 1, pp 19-21, issn 0378-7346, 3 p.Article

Laser Scanning-Based Tissue Autofluorescence/ Fluorescence Imaging (LS-TAFI), a New Technique for Analysis of Microanatomy in Whole-Mount TissuesMORI, Hidetoshi; BOROWSKY, Alexander D; BHAT, Ramray et al.The American journal of pathology. 2012, Vol 180, Num 6, pp 2249-2256, issn 0002-9440, 8 p.Article

A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) -Part I: Pharmacological characterizationWANG, Yi-Xin; LEI ZHAO; HRVATIN, Paul et al.Thrombosis and haemostasis. 2007, Vol 97, Num 1, pp 45-53, issn 0340-6245, 9 p.Article

New insights into factors affecting clot stability: A role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R)BOUMA, Bonno N; MEIJERS, Joost C. M.Seminars in hematology. 2004, Vol 41, Num 1, pp 13-19, issn 0037-1963, 7 p., SUP1Conference Paper